Thomas J Lynch

This inventor holds 22 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 7 EPO patents, primarily in Phytochemical Compositions. Top assignees: Dana-Farber-Cancer Institute Inc., J.m. Huber Corporation, The General Hospital Corporation. Active years: 1998-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas J Lynch. Retrieved from https://idiyas.com/inventor/thomas-j-lynch-2hm6gyxs

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 6)

% Patents Active = 86.4

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 7 (Patent Applications = 9)

Average Co-Inventor Count = 3.3

ph-index = 8

Forward Citations = 520(Granted Patents)

Location History:

Branchburg, GA (US) (2000)
Macon, GA (US) (1998 - 2001)
Roswell, GA (US) (2005 - 2023)
Newton, MA (US) (2007 - 2024)
Elverson, PA (US) (2024)

Company Filing History:

8 out of 1,268

Dana-Farber-Cancer Institute Inc.

patents

8 out of 356

J.m. Huber Corporation

patents

8 out of 3,076

The General Hospital Corporation

6. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2025

Loading Chart...

Areas of Expertise:

Phytochemical Composition

Nutraceuticals

Cancer Treatment

Epidermal Growth Factor

Inverse Emulsion

Polymer Compositions

Paper Strength Agent

Mineral Dispersants

Surface Treated Silicas

Vulcanizable Elastomer

Modified Mineral Filler

Treated Clay Product

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12186341 - Phytochemical/ nutraceutical composition for multimodal prophylaxis against and treatment of viral and bacterial infection and inflammation (2025-01-07),

2. 12006555 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2024-06-11),

3. 11896611 - Phytochemical/ nutraceutical composition for multimodal prophylaxis against and treatment of viral and bacterial infection and inflammation (2024-02-13),

4. 11753580 - Inverse emulsion compositions (2023-09-12),

5. 11299409 - Polymer compositions and methods of use (2022-04-12),

6. 10669589 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2020-06-02),

7. 10378154 - Composition for use as a paper strength agent (2019-08-13),

8. 10000815 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2018-06-19),

9. 9035036 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2015-05-19),

10. 8465916 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2013-06-18),

11. 8105769 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2012-01-31),

12. 7964349 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2011-06-21),

13. 7875213 - Mineral dispersants and methods for preparing mineral slurries using the same (2011-01-25),

14. 7294468 - Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments (2007-11-13),

15. 7262233 - Surface treated silicas (2007-08-28),

Title: Innovator Spotlight: Thomas J. Lynch

Introduction

Thomas J. Lynch is a noteworthy inventor based in Roswell, GA, recognized for his contributions to the fields of phytochemistry and nutraceuticals. With an impressive portfolio of 14 patents, Lynch has dedicated his career to developing innovative compositions aimed at enhancing health and wellness.

Latest Patents

Among his most recent inventions is a groundbreaking phytochemical and nutraceutical composition designed for multimodal prophylaxis against and treatment of viral and bacterial infections, including COVID-19. This composition integrates a unique combination of vitamins, minerals, nutraceuticals, and phytochemicals aimed at boosting immunity and alleviating infections. The formulation may be compounded into various forms such as pills, tablets, powders, capsules, or liquids, to be taken orally multiple times a day. Key components include Vitamin C, Vitamin E, and zinc, combined with carefully selected nutraceuticals, that serve as immune boosters and antiviral agents, alongside anti-inflammatory properties.

Career Highlights

Lynch’s career includes significant positions at reputable companies, including J.M. Huber Corporation and Kemira Oyj. Through his work, he has garnered extensive experience that has undoubtedly influenced his innovative endeavors.

Collaborations

Throughout his career, Thomas J. Lynch has collaborated with notable professionals in his field, including Gary M. Freeman and Carl J. Marshall, Jr. These collaborations have likely contributed to the success and impact of his inventions.

Conclusion

Thomas J. Lynch exemplifies the spirit of innovation in the domain of nutraceuticals. His commitment to developing effective health solutions through his patented inventions not only showcases his ingenuity but also highlights the potential benefits of phytochemicals in combating contemporary health challenges.

Profile summary based on public USPTO records.